Reported about 8 hours ago
Novartis has raised its full-year profit outlook due to strong demand for key cancer medications, with CEO Vas Narasimhan discussing the company's growth strategies, manufacturing expansion in the U.S., and how they plan to navigate potential trade tariffs. Despite some recent dips in sales of certain drugs, Narasimhan expressed confidence in overcoming competition and achieving long-term sales goals.
Source: YAHOO